Category Archives: Cardiology

Ucardia Announces Acquisition of PHAS3; Launches Cardiologist … – Diagnostic and Interventional Cardiology

May 13, 2023 medical

May 8, 2023 Ucardia, a cardiac conditioning software developer, announced today that it has reached an agreement to acquire Phas3, a pioneer in home-based cardiac rehab and fellow industry leader. This acquisition will result in a comprehensive, market-leading solution for providers, payers, and consumers, covering all facets of cardiac rehabilitation, conditioning, and remote monitoring for patients affected by cardiovascular disease (CVD).

"With Phas3's compelling software that allows clinicians a convenient way to remotely monitor and engage their cardiac patients, we are confident we have a market-first product that truly allows for patient- and provider-partnered cardiac care for all modalities of remote care from patients immediately post-discharge from a cardiac event who cannot attend traditional cardiac rehab, to patients looking for a supervised program to strengthen their heart at home," said Nick Weber, Ucardia's co-founder and CEO.

Ucardia and Phas3 will continue to support all existing customers and their patients in the companies' joint portfolio and are excited to begin planning exciting new products and services that take advantage of their combined strengths.

"We are pleased to join the Ucardia family and share the company's vision of serving even more CVD patients with our unique and powerful combination of software and clinical services" said Lucas Rydberg, Phas3's co-founder and CEO.

Jointly with this acquisition, Ucardia is announcing its newest offering,Ucardia-at-Home, a comprehensive remote patient monitoring platform that enables cardiologists and physician practices to enhance the monitoring, engagement, education, and self-management of patients between traditional doctor visits and close the gap in patient care management.

"We see serving the physician practice segment as a natural extension of the missions of both Phas3 and Ucardia continuing to make sure every CVD patient has the opportunity to receive critical monitoring and care while in the comfort and convenience of their home," said Dan Ebeling, co-founder and COO of Phas3. "We believe in extending access to every patient who needs this essential care."

For more information:www.ucardia.com

See the rest here:

Ucardia Announces Acquisition of PHAS3; Launches Cardiologist ... - Diagnostic and Interventional Cardiology

Cardiology

Oxygen therapy improves heart function in patients with long COVID – EurekAlert

May 13, 2023 medical

Barcelona, Spain 10 May 2023: A small randomised trial in patients with post-COVID syndrome has found that hyperbaric oxygen therapy promotes restoration of the hearts ability to contract properly. The research is presented at EACVI 2023, a scientific congress of the European Society of Cardiology (ESC).1

The study suggests that hyperbaric oxygen therapy can be beneficial in patients with long COVID, said study author Professor Marina Leitman of the Sackler School of Medicine, Tel Aviv University and Shamir Medical Centre, Be'er Ya'akov, Israel. We used a sensitive measure of cardiac function which is not routinely performed in all centres. More studies are needed to determine which patients will benefit the most, but it may be that all long COVID patients should have an assessment of global longitudinal strain and be offered hyperbaric oxygen therapy if heart function is reduced.

Most COVID-19 sufferers fully recover, but after the initial illness approximately 1020% of patients develop long COVID, also called post-COVID condition or syndrome.2 Symptoms include shortness of breath, fatigue, cough, chest pain, rapid or irregular heartbeats, body aches, rashes, loss of taste or smell, nausea, vomiting, diarrhoea, headache, dizziness, insomnia, brain fog, depression and anxiety. Patients with post-COVID syndrome may also develop cardiac dysfunction and are at increased risk of a range of cardiovascular disorders.3

This randomised controlled double-blind trial evaluated the effect of hyperbaric oxygen therapy (HBOT) on the cardiac function of long COVID patients. HBOT involves inhalation of 100% pure oxygen at high pressure to increase delivery to the bodys tissues, which is particularly beneficial for tissues that are starved of oxygen due to injury or inflammation. HBOT is an established treatment for non-healing wounds, decompression sickness in divers, carbon monoxide poisoning, radiation injury and certain types of infections

The study enrolled 60 post-COVID syndrome patients with ongoing symptoms for at least three months after having mild to moderate symptomatic COVID-19 confirmed by a PCR test. Both hospitalised and non-hospitalised patients were included. Severe COVID cases were excluded. Patients were randomised to HBOT or a sham procedure in a 1:1 ratio. Each patient had five sessions per week over eight weeks, for a total of 40 sessions. The HBOT group received 100% oxygen through a mask at a pressure of 2 atmospheres for 90 minutes, with 5 minute air breaks every 20 minutes. The sham group breathed 21% oxygen by mask at 1 atmosphere for 90 minutes. All participants underwent echocardiography at baseline (before the first session) and 1 to 3 weeks after the last session.

Echocardiography was used to assess left ventricular global longitudinal strain (GLS), which is a measure of the hearts ability to contract and relax lengthwise. It indicates how well the heart is functioning and can help detect early signs of heart disease. A healthy heart will have a GLS value of around -20% which means that the heart muscle is able to properly contract and relax in the longitudinal direction. Reduced GLS is an early marker that the heart is not able to contract and relax effectively.

At baseline, nearly half of study participants (29 out of 60; 48%) had reduced GLS. Of those, 13 (43%) and 16 (53%) were in the sham and HBOT groups, respectively. The average GLS at baseline across all participants was -17.8%. In the HBOT group, GLS significantly increased from -17.8% at baseline to -20.2% after the intervention (p=0.0001). In the sham group, GLS was -17.8% at baseline and -19.1% after the sessions, with no statistically significant difference between the two measurements.

Professor Leitman said: It was notable that almost half of long COVID patients had impaired cardiac function at baseline according to GLS despite all participants having a normal ejection fraction, which is the standard method for measuring the hearts ability to contract. This means that ejection fraction is not sensitive enough to identify long COVID patients with reduced heart function.

She concluded: The findings suggest that HBOT promotes recovery of cardiac function in patients with post-COVID syndrome. More research is needed to collect long-term results and determine the optimal number of sessions for maximum therapeutic effect.

ENDS

Authors: ESC Press OfficeMobile: +33 (0)489 872 075Email: press@escardio.org

Notes to editor

Funding: None.

Disclosures: None.

References and notes

1The abstract The effect of hyperbaric oxygen therapy on myocardial function in post-COVID syndrome patients: a randomized controlled trial will be presented during the session COVID which takes place on 10 May at 11:30 CEST at Moderated ePosters 1.

2World Health Organization: Coronavirus disease (COVID-19): Post COVID-19 condition.

3Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28:583590.

About EACVI 2023 #EACVI2023

EACVI 2023 is the first patient-focused and unified multi-modality congress. It is organised by the European Association of Cardiovascular Imaging (EACVI) of the European Society of Cardiology (ESC).

About the European Association of Cardiovascular Imaging (EACVI)

The European Association of Cardiovascular Imaging(EACVI) - a branch of the ESC - is the world leading network of Cardiovascular Imaging (CVI) experts, gathering four imaging modalities under one entity (Echocardiography, Cardiovascular Magnetic Resonance, Nuclear Cardiology and Cardiac Computed Tomography). Its aim is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging. The EACVI welcomes over 11,000 professionals including cardiologists, sonographers, nurses, basic scientists and allied professionals.

About the European Society of Cardiology

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

Information for journalists about registration for EACVI 2023

EACVI 2023 will be held 10 to 12 May at the Fira Gran Via, Hall 8, in Barcelona, Spain. Explore the scientific programme.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

See original here:

Oxygen therapy improves heart function in patients with long COVID - EurekAlert

Cardiology

AIMed Global Summit 2023 to Focus on Changing Healthcare One … – Diagnostic and Interventional Cardiology

May 13, 2023 medical

May 10, 2023 The AiMed Global Summit will be held June 4-7, 2023, in SanDiego, Calif, and program details offered include a comprehensive agenda of key leaders on artificial intelligence (AI) and its application and implications on healthcare. The event will offer six high-value tracks, 200+ speakers, a dozen keynotes, pre and post summit partner events over three days, offering attendees a chance to gain insights into the latest use cases, perspective and approaches in AI medicine. Participants will also have an opportunity to access the Smart Health Expo, network with 1500 healthcare game changers and hear from top health AI luminaries, facilitating expert insights, proven best practices and real-world success stories, and interact with more than 60 sponsoring exhibitors, according to AiMed Global Summit planners.

An overview of AiMed Global Summit news features and program highlights has been updated by the editorial team at Imaging Technology News/ITN (itnonline.com) and Diagnostic and Interventional Cardiology/DAIC (dicardiology.com) who will be on site and offer ongoing coverage.

Representatives from the following top healthcare facilities across the country have been tapped to speak during the Summit, and include but are not limited to: Tenet Health, Mayo Clinic, University of California, Duke AI Health, Harvard Medical School, Phoenix Childrens, Rady Childrens, University of Texas MD Andersen Cancer Center, and CHOC Childrens.

Additionally, leaders from leading associations are scheduled to participate as Speaker Advisors, including President-Elect of the American Medical Association, Jesse Ehrenfeld, MD, providing An Update from the AMA on June 5, as well as representatives from the American Hospital Association, and the American College of Cardiology.

Major business speakers include: Bayer - Head of Medical Affairs, Digital Radiology, Ankur Sharma;Nuance Chief Medical Information Officer, Matthew Lungren, MD, MPH;AWS Principal Business Devt Officer-Academic Medical Centers, Rod Tarrago, MD;Google Health Chief Clinical Officer, Michael Howell; Clinical Lead, Public & Population Health, Von Nguyen, MD;Philips Global Practice Leader, Edgar Van Zoelen.

During AiMed 2023, content will be split across six dedicated tracks which planners have described as focusing on these areas:

1) From Data to Delivery:Uncovering how data is being leveraged to drive innovation and help change the way clinicians and healthcare business leaders identify, manage and treat patients.

2) Population Health & Equity:Participants of this track will discuss, question and collaborate on developing, validating, and testing AI approaches for risk prediction, bias situations and areas of prevalence, diagnostics and decision making to provide value for cohorts and improving health equity.

3) Ethics & Regulation:With a lens of ensuring humans remain in the loop, discussions explore the nuances of AI so that it promotes well-being, patient equity, human safety and the public interest. This track deep dives into the R.E.A.L (regulation, ethics, accountability and legal) issues around AI and the wider considerations.

4) Tools & Deployment Track:Participants will be able consider use cases and lessons learned to aid your deployment decisions and benefit from the transformational opportunities that AI can provide in medicine and healthcare operations. Dig into the AI tool kit and explore RPA, wearable technology, NLP, digital twins, neural networks, machine and deep learning, extended reality, etc. For those wondering how to implement AI in their roles, scale up, just getting started or already an expert.

5) Strategies for Healthcare Leaders:This track translates these nuances in detail to build sector resilience as we reimagine the future of healthcare with AI. Seeks to answer the question: do we have the policy, strategy, funding models, education and people in place to deliver at scale?

6) Application in Clinical Domains:As the scope increases, providing clinicians with further insights into patient conditions, this track shares the latest applications and use cases across clinical domains.

The College of Healthcare Information Management Executives (CHiME) is hosting the Innovation in Clinical Informatics as part of AiMed Global Summits Pre-Summit Program onon Sunday, June 4 and Monday, June 5.CHiME is the professional organization for Chief Information Officers and other senior healthcare IT leaders. CHiME enables its members and business partners to collaborate, exchange ideas, develop professionally and advocate the effective use of information management to improve the health and care throughout the communities they serve. Learn from leading experts at this jam-packed program led by C-level healthcare executives, delivering the roadmap to implement next-gen solutions in your practice.

ABAIM AI Review Course

The American Board of Artificial Intelligence in Medicine (ABAIM) is hosting an AI Review Course as part of AiMed Global Summits Pre-Summit Programming. ABAIM is a nascent multidisciplinary AI advisory group of domain experts formed to provide educational content and a certification examination for healthcare participants in the course as they embark on their journey of AI in medicine. In partnership with AiMed Global Summit, ABAIM is offering a CME-accredited course led by industry experts. This one-day course is the perfect foundation for gaining an educational certification assessment in AI. With a live faculty of industry leading experts, it is not to be missed! Learn from AiMed Founder Anthony Chang, and ABAIM executives leading the way for AI in medicine, and join the conversation in developing best practices set to advance digital healthcare. The activity will be worth eightcredit hours based on the current schedule.

The AiMed 2023 Networking Reception will also take place Sunday evening.

CHOCs Chief Intelligence and Innovation Officer, Anthony Chang, MD, MBA, MPH, MS, is the Chairman and Founder of AIMed, who will join with AIMed CEO Freddy White to deliver the Grand Opening Keynote address on Monday, June 5.

The Headlines Stage, featuring expert sources on key topics daily, will kick off on day one with an address focused on AI Foundations: 2023 Update of AI in Healthcare. Presenters joining AIMed Founder Chang for this session include Alfonso Limon of Oneirix Labs,Karen B Seagraves, PhD,Sharief Taraman, MD, University of California, Irvine School of Medicine.

Official opening of the AiMed Smart Health Expo featuring vendors providing solutions, services, inspiration, as well as open floor layout for optimized networking and making connections over refreshments.

AI Foundations: a foundation level masterclass provides a multidisciplinary and comprehensive overview of the principles and application of data science, artificial intelligence and intelligence-based medicine. Covering its basic concepts and its real-life applications at a top level. This masterclass is a must attend for any clinician and practitioner seeking to strengthen their foundational level knowledge of AI.

Additionally, the Smart Health Expo opens Monday, June 5, offering an open floor plan for improved networking.Subspecialty Group Meetups will also take place on the first day of the summit.

Breakfast Workshops will allow participants to take a deep dive into a range of key areas impacting AI in medicine, from Leveraging Natural Language in Healthcare to a C-Suite Primer and additional sessions.

Breakout Tracks allow attendees to engage in all aspects impacting their work: From Data to Delivery; Ethics & Regulation; Population Health & Equity; Tools & Deployment; Strategies for Healthcare Leaders; Applications in Clinical Domains; The Computer Lab.

The Headliners Roundup for June 6 features a session, Whats Influencing Clinical Medicine and Healthcare Today? and will include Michael Howell, MD,Google Health, Jack Hampson, ofDeeper Insights, and PatricioA. Frias, MD,Rady Children's Hospital.

The Shark Tank Startup Showcase on June 6 will allow the shortlisted five start-ups four minutes to deliver a shark tank style pitch of their solution followed by six minutes for Q&A. The prestigious judging panel of healthcare entrepreneurs and VCs who invest in seed rounds will rank each pitch to determine the winner.

AI Champions Awards will presented as an evening to celebrate and recognize the great people and organizations that are helping to drive the agenda for artificial intelligence in healthcare. To be held the evening of Tuesday, June 6, the AI Champion Awards is described as an evening to celebrate and recognize the great people and organizations that are helping to drive the agenda for artificial intelligence in healthcare.

On the final day of AiMed 2023, another 15 sessions will take place, including Breakfast Workshops focused on Digital Twins, Operationalizing AI and other hot topics. Also on June 7, the AiMed Abstract Competition will give students, early and established career clinicians and data scientists the opportunity to present posters to an esteemed panel of judges.

Closing out the 3-day event on the Headliners Stage will be a series of keynotes from senior healthcare leaders. Breakout tracks covering 6 key areas will offer Stargazing AI in Healthcare: What Does the 5 Year Roadmap Ahead Look Like?

Panelists include: Anthony Chang MD, MBA, MPH, MS, of CHOC and Founder, AiMed;Eric Eskioglu, MD, MBA, formerly withNovant Health; Eric Wicklund, from mHealthIntelligence; G. Hamilton Baker, MD, of The Medical University of South Carolina;Karen B Seagraves, PhD, MPH;and William W Feaster, MD, CHOC Children's Hospital.

AiMed is described as a driving force ensuring the healthcare sector is not left behind, whose stated goals are to eradicate challenges, define AI enabled solutions and create an efficient workplace, with patient outcomes at its core. The organization notes that its aim is to assist medical professionals to discover new ways to incorporate advances in technology to help the way they work.The Childrens Hospital of Orange County (CHOC) Medical Intelligence and Innovation Institute (MI3) is funded by the Sharon Disney Lund Foundation with the purpose of advancing data science and artificial intelligence in medicine around the world. Our vision is for this institute as well as AiMed to serve as a clarion call to start a revolution to embrace this exciting new paradigm for healthcare and medicine.

For more information: https://ai-med.io

AiMed Global Summits Lineup Announced

AiMed 2023: Changing Healthcare One Connection at a Time

Find more AiMed23 conference coverage here

See the rest here:

AIMed Global Summit 2023 to Focus on Changing Healthcare One ... - Diagnostic and Interventional Cardiology

Cardiology

New report finds action is required to protect UK health research – Imperial College London

May 13, 2023 medical

A new report from the Academy of Medical Sciences has outlined that the UK needs to do more to retain its exceptional strengths in health research.

The report titled Future-proofing UK Health Research: a people-centred, coordinated approachwas produced by 30 experts from across the UK, including Imperials Dr Rasha Al-Lamee, Clinical Senior Lecturer at the National Heart and Lung Institute, Imperial College London and cardiology consultant Imperial College Healthcare NHS Trust.

The report calls for coordinated action to secure a sustainable future for research and deliver maximum health benefits for people everywhere, which involves Governments across the UK, public and charitable funders, higher education institutions, industry, NHS leaders, patients, carers and the public.

Listen to Dr Al-Lamee on BBC Radio 4 Today Programme(from 51m 53s)

It concludes that UK health research is in danger of being taken for granted and sets out what needs to be done to improve and future-proof it.

The importance of clinical academics was highlighted as being crucial to support the over-burdened NHS and calls on regulators, funders, the NHS and universities to improve support for clinical academics and pilot a scheme where healthcare professionals have protected time for research.

Dr Rasha Al-Lamee works jointly between Imperials National Heart and Lung Institute and as a cardiology consultant at Imperial College Healthcare NHS Trust and spends 70% of her work-life running clinical trials on how to relieve the symptoms of heart disease and 30% of her time seeing patients.

Dr Al-Lamee noted that"hospitals doing research have better patient outcomes overall.

Despite this, there has been a decline of almost a quarter of the number of clinical academics at my career level across the UK over the last decade.

To avoid detrimental effects on patients and healthcare workers like me, the sector needs to make it easier to hold these dual careers in a secure and flexible way.

Some ofthe report's other key findings include the need to place people at the heart of the UK health research system by improving research culture and career structures, maximise the research potential of the NHS and, crucially, ensure that the true cost of excellent health research is adequately covered by addressing the current model of research funding where universities are required to cross-subsidise research costs from international student fee income.

Original post:

New report finds action is required to protect UK health research - Imperial College London

Cardiology

Common Sedative vs Afib; Fishbone Pierces Heart; Oral PCSK9 … – Medpage Today

May 5, 2023 medical

When people actually prove their adherence to the Mediterranean diet using blood tests, this eating pattern was associated with stronger protection from type 2 diabetes than previously thought. (PLOS Medicine)

The global burden of cardiovascular deaths attributable to very cold and very hot temperatures increased from 1990 to 2019. (European Journal of Preventive Cardiology)

The common sedative dexmedetomidine was associated with reduced new-onset atrial fibrillation (Afib) in ICU patients. (JAMA Network Open)

Afib was associated with an overabundance of certain species in the gut microbiome. (eBioMedicine)

Procedural efficacy was high in the early experience with the new Heliostar irrigated radiofrequency balloon, which was designed to give operators impedance values that quantify the grade of contact during pulmonary vein isolation. (EP Europace)

An interatrial shunt without a permanent implant? Radiofrequency-energy excision of the interatrial septum showed promise in terms of pulmonary capillary wedge pressure and functional improvement at 6 months. (JACC: Heart Failure)

DELIVER trial participants derived consistent benefits from dapagliflozin (Farxiga) across the spectrum of ejection fraction. (JAMA Cardiology)

The case where a swallowed fishbone, nearly an inch long, pierced through the heart into the left atrium and caused a Staphylococcus aureus infection. (European Heart Journal)

FDA cleared the Heart Seat -- a smart toilet seat that measures heart rate and oxygen saturation -- maker Casana announced.

Medtronic said the FDA approved its next-generation Micra AV2 and VR2 leadless pacemakers featuring 40% more battery life than older devices.

The Endurant abdominal aortic aneurysm stent graft system boasted 94.7% freedom from aneurysm-related mortality and 64.1% sac regression in 10-year postmarketing data, Medtronic also announced.

Among young people who survive acute myocardial infarction (MI), women are disproportionately more likely to be rehospitalized for cardiac and noncardiac reasons. (Journal of the American College of Cardiology)

After coronary artery bypass grafting, subsequent angioplasty on the graft, as opposed to the native artery, was tied to a higher 5-year MI risk. (Clinical Cardiology)

Merck scientists report phase I data supporting the macrocyclic peptide MK-0616 as an oral PCSK9 inhibitor that may lower LDL cholesterol. (Circulation)

People with more painful areas on their body were prone to MI but not stroke. (JACC: Advances)

In 2000-2014, Black Americans with better survival rates tended to be those born in Africa, the Caribbean, South America, and Central America. (Journal of the American Heart Association)

A country with fewer than 10 cardiac specialists, Zambia just had its first total aortic arch replacement surgery with guidance from University of Michigan surgeons. (Michigan Medicine)

MPI 8, an anticoagulant targeting polyphosphate, is being developed for potential clinical use without bleeding side effects. (Nature Communications)

Scientists are hoping that their "vein on a chip" could be a good lab model of blood clot formation, according to the University of Birmingham.

Nicole Lou is a reporter for MedPage Today, where she covers cardiology news and other developments in medicine. Follow

Read this article:

Common Sedative vs Afib; Fishbone Pierces Heart; Oral PCSK9 ... - Medpage Today

Cardiology

Balloon Pulmonary Angioplasty for Treatment of CTEPH in Patients … – The Cardiology Advisor

May 5, 2023 medical

Balloon Pulmonary Angioplasty for Treatment of CTEPH in Patients ... The Cardiology Advisor

PET Nuclear Medicine Market By Applications ( Oncology, Cardiology, Neurology, Other PET Applications ) – openPR

May 5, 2023 medical

PET Nuclear Medicine Market

Download Sample PDF at https://www.theinsightpartners.com/sample/TIPRE00015978/?utm_source=OpenPR&utm_medium=10379

Key Players Analysis: Cardinal Health Curium GE Healthcare Lantheus Medical Imaging, Inc. Bayer AG Bracco Imaging S.P.A. Eczacibasi-Monrol Nuclear Products Nordion, Inc. (A Subsidiary of Sterigenics International) Advanced Accelerator Applications (AAA) (A Part of Novartis) NTP Radioisotopes Soc, LTD.

The report covers key developments in the PET Nuclear Medicine market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from PET Nuclear Medicine market are anticipated to have lucrative growth opportunities in the future with the rising demand for PET Nuclear Medicine in the global market. Below mentioned is the list of few companies engaged in the PET Nuclear Medicine market.

Speak to Analyst @ https://www.theinsightpartners.com/speak-to-analyst/TIPRE00015978?utm_source=OpenPR&utm_medium=10379

Research report has been compiled by studying the market in-depth along with drivers, opportunities, restraints & other strategies as well as new-developments that can help a reader to understand the exact situation of the market along with the factors that can limit or hamper the market growth and the report also has been updated with Impacts & effects of Coronavirus pandemic and how it has influenced consumer behavior & the growth of the market as well as industries.

MARKET SEGMENTATIONThe PET nuclear medicine market is segmented on the basis of type and application. Based on type, the market is segmented as F-18, Rb-82, Other PET Isotopes. On the basis of application, the market is categorized as oncology, cardiology, neurology, and other pet applications.

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the PET Nuclear Medicine Market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The PET Nuclear Medicine Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

Get a Full Copy @ https://www.theinsightpartners.com/buy/TIPRE00015978/?utm_source=OpenPR&utm_medium=10379

Contact USContact Person : Sameer JoshiPhone : +1-646-491-9876E-mail : sales@theinsightpartners.com

About US

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Food and Beverages, Consumers and Goods, Chemicals and Materials.

This release was published on openPR.

See more here:

PET Nuclear Medicine Market By Applications ( Oncology, Cardiology, Neurology, Other PET Applications ) - openPR

Cardiology

Statin Misinformation on Social Media Flagged by AI – Medscape

May 5, 2023 medical

Using artificial intelligence (AI) to analyze large amounts of information from social media platforms generated some novel insights into public perceptions about statins, results of a new study show.

The study, which used AI to analyze discussions about statins on the social media platform Reddit, corroborated previously documented reasons for statin hesitancy, including adverse effect profiles, and general disenfranchisement with healthcare.

But it also found novel points of discourse including linking statins to COVID-19 outcomes, and the role of cholesterol, statins, and the ketogenic diet.

"We used AI to tell us what is being discussed about statins on social media and to quantify the information in topics that people think are important," senior study author Fatima Rodriguez, MD, MPH, Stanford University School of Medicine, Stanford, California, told theheart.org | Medscape Cardiology.

"Some of the themes were surprising to us. While we expected discussion on side effects, we were surprised to see so much discussion refuting the idea that increased levels of LDL were detrimental. There were also a large amount of posts on statin use being correlated to COVID outcomes. Our findings show how widespread this misinformation is," she said.

"As a preventative cardiologist I spend a lot of my time trying to get patients to take statins, but patients often rely on social media for information, and this can contain a lot of misinformation.

"People tend to be more honest on online forums than they are in the doctor's office, so they are probably asking the questions and having discussions on subjects they really care about. So, understanding what is being discussed on social media is very valuable information for us as clinicians."

The study was published online April 24 in JAMA Network Open.

The researchers analyzed all statin-related discussions on Reddit that were dated between January 1, 2009, and July 12, 2022. Statin- and cholesterol-focused communities were identified to create a list of statin-related discussions. An AI pipeline was developed to cluster these discussions into specific topics and overarching thematic groups.

A total of 10,233 unique statin-related discussions and 5,188 unique authors were identified. A total of 100 discussion topics were identified and classified into six overarching thematic groups: (1) ketogenic diets, diabetes, supplements, and statins; (2) statin adverse effects; (3) statin hesitancy; (4) clinical trial appraisals; (5) pharmaceutical industry bias and statins; and (6) red yeast rice and statins.

Several examples of statin-related misinformation were identified, including distrust of the hypothesis that LDL-C has a causal association with heart disease. Discussions included quotes such as "I think LDL is pretty much irrelevant. Your HDL and triglycerides are far more important."

Other topics suggested that certain natural supplements would be an acceptable alternative to statins. Quotes included: "Red yeast rice is a statin basically, by the way," and "statins are basically mycotoxins and deplete you of fat-soluble nutrients, like coQ10, vit D, K, A and E, and in all likelihood through these depletions worsen cardiovascular health."

The researchers also looked at temporal trends and found that these sorts of discussions have increased over time.

One of the common themes identified was using the ketogenic diet phenomenon as an argument against increased cholesterol levels being bad for health.

Rodriguez elaborated: "People think the ketogenic diet is healthy as they lose weight on it. And as it can be associated with a small increase in LDL cholesterol there was a lot of opinion that this meant increasing LDL was a good thing."

The researchers also conducted a sentiment analysis, which designated topics as positive, negative or neutral with regard to statins.

"We found that almost no topic was positive. Everything was either neutral or negative.This is pretty consistent with what we are seeing around hesitancy in clinical practice, but you would think that maybe a few people may have a positive view on statins," Rodriguez commented.

"One of the problems with statins and lowering cholesterol is that it takes a long time to see a benefit, but this misinformation will result in some people not taking their medication," she added.

Rodriguez noted that in this study AI is augmenting, not replacing, what clinicians and researchers do. "But it is a valuable tool to scan a large volume of information, and we have shown here it can generate new insights that we may not have thought of.It's important to know what's out there so we can try and combat it."

She pointed out that patients don't read the medical literature showing the benefits of statins but rather rely on social media for their information.

"We need to understand all sorts of patient engagement and use the same tools to combat this misinformation. We have a responsibility to try and stop dangerous and false information from being propagated," she commented.

"These drugs are clearly not dangerous when used in line with clinical guidelines and they have been proven to have multiple benefits again and again, but we don't see those kinds of discussions in the community at all. We as clinicians need to use social media and AI to give out the right information. This could start to combat all the misinformation out there."

JAMA Network Open. Published online April 24, 2023. Full text

For more from theheart.org | Medscape Cardiology, join us on Twitter and Facebook

Continue reading here:

Statin Misinformation on Social Media Flagged by AI - Medscape

Cardiology

Mobile phone calls linked with increased risk of high blood pressure – EurekAlert

May 5, 2023 medical

Sophia Antipolis, 5 May 2023: Talking on a mobile for 30 minutes or more per week is linked with a 12% increased risk of high blood pressure compared with less than 30 minutes, according to research published today in European Heart Journal Digital Health, a journal of the European Society of Cardiology (ESC).1

Its the number of minutes people spend talking on a mobile that matter for heart health, with more minutes meaning greater risk, said study author Professor Xianhui Qin of Southern Medical University, Guangzhou, China. Years of use or employing a hands-free set-up had no influence on the likelihood of developing high blood pressure. More studies are needed to confirm the findings.

Almost three-quarters of the global population aged 10 and over own a mobile phone.2 Nearly 1.3 billion adults aged 30 to 79 years worldwide have high blood pressure (hypertension).3 Hypertension is a major risk factor for heart attack and stroke and a leading cause of premature death globally. Mobile phones emit low levels of radiofrequency energy, which has been linked with rises in blood pressure after short-term exposure. Results of previous studies on mobile phone use and blood pressure were inconsistent, potentially because they included calls, texts, gaming, and so on.

This study examined the relationship between making and receiving phone calls and new-onset hypertension. The study used data from the UK Biobank. A total of 212,046 adults aged 37 to 73 years without hypertension were included. Information on the use of a mobile phone to make and receive calls was collected through a self-reported touchscreen questionnaire at baseline, including years of use, hours per week, and using a hands-free device/speakerphone. Participants who used a mobile phone at least once a week to make or receive calls were defined as mobile phone users.

The researchers analysed the relationship between mobile phone usage and new-onset hypertension after adjusting for age, sex, body mass index, race, deprivation, family history of hypertension, education, smoking status, blood pressure, blood lipids, inflammation, blood glucose, kidney function and use of medications to lower cholesterol or blood glucose levels.

The average age of participants was 54 years, 62% were women and 88% were mobile phone users. During a median follow up of 12 years, 13,984 (7%) participants developed hypertension. Mobile phone users had a 7% higher risk of hypertension compared with non-users. Those who talked on their mobile for 30 minutes or more per week had a 12% greater likelihood of new-onset high blood pressure than participants who spent less than 30 minutes on phone calls. The results were similar for women and men.

Looking at the findings in more detail, compared to participants who spent less than 5 minutes per week making or receiving mobile phone calls, weekly usage time of 30-59 minutes, 1-3 hours, 4-6 hours and more than 6 hours was associated with an 8%, 13%, 16% and 25% raised risk of high blood pressure, respectively. Among mobile phone users, years of use and employing a hands-free device/speakerphone were not significantly related to the development of hypertension.

The researchers also examined the relationship between usage time (less than 30 minutes vs. 30 minutes or more) and new-onset hypertension according to whether participants had a low, intermediate or high genetic risk of developing hypertension. Genetic risk was determined using data in the UK Biobank. The analysis showed that the likelihood of developing high blood pressure was greatest in those with high genetic risk who spent at least 30 minutes a week talking on a mobile they had a 33% higher likelihood of hypertension compared to those with low genetic risk who spent less than 30 minutes a week on the phone.

Professor Qin said: Our findings suggest that talking on a mobile may not affect the risk of developing high blood pressure as long as weekly call time is kept below half an hour. More research is required to replicate the results, but until then it seems prudent to keep mobile phone calls to a minimum to preserve heart health.

ENDS

Authors:ESC Press OfficeMobile: +33 (0)7 8531 2036Email:press@escardio.org

Funding: The study was supported by the National Key Research and Development Program (2022YFC2009600, 2022YFC2009605), and the National Natural Science Foundation of China (81973133, 81730019).

Disclosures: The authors have no conflicts of interest to report.

References

1Ye Z, Zhang Y, Zhang Y, et al. Mobile phone calls, genetic susceptibility and new-onset hypertension: results from 212,046 UK Biobank participants. Eur Heart J Digit Health. 2023. doi:10.1093/ehjdh/ztad024.

Link will go live on publication:

https://academic.oup.com/ehjdh/article-lookup/doi/10.1093/ehjdh/ztad024

2International Telecommunication Union. Measuring digital development: facts and figures 2022. https://www.itu.int/hub/publication/d-ind-ict_mdd-2022/

3World Health Organization. Key facts on hypertension. https://www.who.int/news-room/fact-sheets/detail/hypertension.

About the European Society of Cardiology

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

About European Heart Journal Digital Health

European Heart Journal Digital Health is the official digital health journal of the European Society of Cardiology. It covers the whole sphere of cardiovascular medicine, from all perspectives of digital health.

European Heart Journal - Digital Health

Mobile phone calls linked with increased risk of high blood pressure - EurekAlert